Literature DB >> 17220392

Experiences of living with non-cancer-related lymphedema: implications for clinical practice.

Lisa K Bogan1, Janet M Powell, Brian J Dudgeon.   

Abstract

Lymphedema is a chronic medical condition caused by lymphatic insufficiency that can lead to extreme swelling and susceptibility to infection. Physical and psychosocial effects of the condition can have a significant impact on an individual's life and level of participation. Research about experiences of individuals living with lymphedema has focused primarily on women with breast cancer, yet individuals with non-cancer-related lymphedema are a distinct group. In this study, the authors used qualitative description to explore the experience of 7 individuals living with advanced and complicated cases of lymphedema who had been treated in an inpatient setting. Findings reveal the extensive impact lymphedema has on those who live with it. Participants spoke of difficulty finding a correct diagnosis and effective treatment, the importance of their inpatient experiences, and the challenges of daily self-management. The authors make recommendations to increase lymphedema awareness, promote inpatient treatment programs, and create effective self-management techniques.

Entities:  

Mesh:

Year:  2007        PMID: 17220392     DOI: 10.1177/1049732306297660

Source DB:  PubMed          Journal:  Qual Health Res        ISSN: 1049-7323


  10 in total

1.  Lymphedema Quality of Life Inventory (LyQLI)-Development and investigation of validity and reliability.

Authors:  Pia Klernäs; Aina Johnsson; Vibeke Horstmann; Linda J Kristjanson; Karin Johansson
Journal:  Qual Life Res       Date:  2015-01-30       Impact factor: 4.147

Review 2.  Psychosocial impact of lymphedema: a systematic review of literature from 2004 to 2011.

Authors:  Mei R Fu; Sheila H Ridner; Sophia H Hu; Bob R Stewart; Janice N Cormier; Jane M Armer
Journal:  Psychooncology       Date:  2012-10-09       Impact factor: 3.894

3.  The impact of lower limb chronic oedema on patients' quality of life.

Authors:  Adelene Greene; Pauline Meskell
Journal:  Int Wound J       Date:  2016-08-04       Impact factor: 3.315

4.  The challenges of managing complex lymphoedema/chronic oedema in the UK and Canada.

Authors:  Philip A Morgan; Susie Murray; Christine J Moffatt; Amanda Honnor
Journal:  Int Wound J       Date:  2011-08-17       Impact factor: 3.315

5.  Illustrating the (in)visible: understanding the impact of loss in adults living with secondary lymphedema after cancer.

Authors:  Roanne Thomas; Ryan Hamilton
Journal:  Int J Qual Stud Health Well-being       Date:  2014-08-21

6.  Teaching self-management skills in persons with chronic lower limb swelling and limited mobility: evidence for usability of telerehabilitation.

Authors:  Becky L Faett; David M Brienza; Mary Jo Geyer; Leslie A Hoffman
Journal:  Int J Telerehabil       Date:  2013-06-11

7.  Worldwide assessment of healthcare personnel dealing with lymphoedema.

Authors:  Henrike Schulze; Marisa Nacke; Christoph Gutenbrunner; Catarina Hadamitzky
Journal:  Health Econ Rev       Date:  2018-04-16

8.  Psychometric evaluation of the Persian version of the Lymphedema Life Impact Scale (LLIS, version 1) in breast cancer patients.

Authors:  Shahpar Haghighat; Ali Montazeri; Farid Zayeri; Mandana Ebrahimi; Jan Weiss
Journal:  Health Qual Life Outcomes       Date:  2018-06-28       Impact factor: 3.186

9.  LIMPRINT: The UK Experience-Subjective Control of Swelling in Patients Attending Specialist Lymphedema Services.

Authors:  Christine J Moffatt; Vaughan Keeley; Andrew Hughes; Kath Clark; Jill Lisle; Margaret Benson; Rebecca Gaskin; Martina Sykorova; Eleanor Dring; Susie Murray; Gregoire Mercier; Isabelle Quere; Peter J Franks
Journal:  Lymphat Res Biol       Date:  2019-04       Impact factor: 2.589

10.  LIMPRINT: Health-Related Quality of Life in Adult Patients with Chronic Edema.

Authors:  Gregoire Mercier; Jenica Pastor; Christine Moffatt; Peter Franks; Isabelle Quéré
Journal:  Lymphat Res Biol       Date:  2019-04       Impact factor: 2.589

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.